Huntsman Corp (HUN.N)
14 Dec 2018
The global pharmaceutical company Fresenius received a rude shock in the summer of 2017 when Akorn, the generic drugmaker Fresenius had agreed to acquire for $4.75 billion, reported its quarterly financial results. The results were terrible – far worse than Fresenius’ gloomiest projection. Fresenius CEO Stephan Sturm considered the Akorn results the biggest personal embarrassment of his career. Within weeks, the company hired Paul Weiss Rifkind Wharton & Garrison to advise it could w
ZURICH, Sept 10 Saudi Basic Industries Corp won approvals to complete its purchase of 24.99 percent of Clariant, the Swiss speciality chemicals maker said on Monday, clearing the way for the two companies to intensify their cooperation.
NEW YORK Atlantic Investment Management's Alex Roepers recommended Huntsman Corp as his best idea on Wednesday during the Delivering Alpha conference, sending the shares up nearly 4 percent.